<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ginseng Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ginseng Res</journal-id><journal-id journal-id-type="pmc-domain-id">1977</journal-id><journal-id journal-id-type="pmc-domain">jginsres</journal-id><journal-title-group><journal-title>Journal of Ginseng Research</journal-title></journal-title-group><issn pub-type="ppub">1226-8453</issn><issn pub-type="epub">2093-4947</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12223531</article-id><article-id pub-id-type="pmcid-ver">PMC12223531.1</article-id><article-id pub-id-type="pmcaid">12223531</article-id><article-id pub-id-type="pmcaiid">12223531</article-id><article-id pub-id-type="pmid">40621083</article-id><article-id pub-id-type="doi">10.1016/j.jgr.2025.04.002</article-id><article-id pub-id-type="pii">S1226-8453(25)00039-9</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Ginsenoside Rg5 inhibits platelet aggregation by regulating GPVI signaling pathways and ferric chloride-induced thrombosis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Akram</surname><given-names initials="AW">Abdul Wahab</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Shin</surname><given-names initials="JH">Jung-Hae</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Batmunkh</surname><given-names initials="U">Uyanga</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Saba</surname><given-names initials="E">Evelyn</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Kang</surname><given-names initials="YM">Yong-Myung</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Jung</surname><given-names initials="S">Sunjun</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Han</surname><given-names initials="JE">Jee Eun</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Kim</surname><given-names initials="SD">Sung Dae</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Kwak</surname><given-names initials="D">Dongmi</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Kwon</surname><given-names initials="HW">Hyuk-woo</given-names></name><email>kwonhw@kdu.ac.kr</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Rhee</surname><given-names initials="MH">Man Hee</given-names></name><email>rheemh@knu.ac.kr</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><aff id="aff1"><label>a</label>Department of Veterinary Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea</aff><aff id="aff2"><label>b</label>Department of Veterinary Biomedical Sciences, Faculty of Veterinary and Animal Sciences, Pir Mehr Ali Shah Arid Agriculture University, Rawalpindi, Pakistan</aff><aff id="aff3"><label>c</label>Department of Biomedical Laboratory Science, Far East University, Eumseong, Republic of Korea</aff><aff id="aff4"><label>d</label>Institute for Veterinary Biomedical Science, Kyungpook National University, Daegu, Republic of Korea</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. Department of Biomedical Laboratory Science, Far East University, 76-32, Daehak-gil, Gamgok-myeon, Eumseong-gun, Chungcheongbuk-do, 27601, Republic of Korea. <email>kwonhw@kdu.ac.kr</email></corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author. Man Hee Rhee. Laboratory of Physiology and Cell Signaling, College of Veterinary Medicine, Kyungpook National University, Daegu, 41566, Republic of Korea. <email>rheemh@knu.ac.kr</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>4</month><year>2025</year></pub-date><volume>49</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">492145</issue-id><fpage>460</fpage><lpage>469</lpage><history><date date-type="received"><day>21</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-07 09:25:16.833"><day>07</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Korean Society of Ginseng. Publishing services by Elsevier B.V.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>Platelet hyperactivation is a major factor in thrombotic complications such as myocardial infarction and ischemic stroke. Ginsenoside Rg5 is a minor ginsenoside, and among its various beneficial pharmacological effects, its antithrombotic potential has not been extensively studied.</p></sec><sec><title>Methods</title><p>Human platelets were isolated and treated with Rg5 (35-100&#160;&#956;M) before stimulation with agonists such as collagen, thrombin, and U46619. Platelet aggregation, granule secretion, calcium mobilization, thromboxane A<sub>2</sub> production, fibrinogen binding, and clot retraction were evaluated. The effects of Rg5 on signaling pathways were determined via Western blot analysis of key proteins. <italic toggle="yes">In vivo</italic>, the antithrombotic efficacy was assessed using ferric chloride (FeCl<sub>3</sub>)-induced thrombosis in mice.</p></sec><sec><title>Results</title><p>Rg5 dose-dependently inhibited collagen-induced platelet aggregation (IC<sub>50</sub>&#160;=&#160;42.5&#160;&#956;M) and selectively inhibited GPVI-mediated signaling compared to thrombin and U46619. Rg5 suppressed intracellular calcium mobilization, granule secretion, and thromboxane A<sub>2</sub> production, with no cytotoxicity observed. Rg5 downregulated key signaling proteins (p-PI3K, p-AKT, p-cPLA2, and p-p38) while upregulating p-VASP (S157 and S239), suggesting its role in elevating cyclic nucleotide signaling. Additionally, Rg5 inhibited CD162 expression that was induced in the presence of collagen and oxidized low-density lipoprotein. It also prevented fibrinogen and fibronectin binding and significantly reduced clot retraction. <italic toggle="yes">In vivo</italic>, Rg5 (20&#160;mg/kg) significantly prolonged the carotid artery occlusion time and prevented thrombus formation, outperforming aspirin (100&#160;mg/kg).</p></sec><sec><title>Conclusion</title><p>Ginsenoside Rg5 exhibits potent antiplatelet activity by selectively targeting GPVI-mediated platelet activation and modulating key intracellular signaling pathways. These results suggest that Rg5 could be utilized to develop safer and natural antiplatelet therapies.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Anti-platelet effects</kwd><kwd>Cardioprotective effects</kwd><kwd>FeCl<sub>3</sub>-Induced thrombosis</kwd><kwd>Ginsenoside Rg5</kwd><kwd>GPVI signaling</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Cardiovascular diseases (CVD) are the leading cause of mortality worldwide [<xref rid="bib1" ref-type="bibr">1</xref>], responsible for over 17.3 million deaths annually, a number projected to increase to 23.6 million by 2030 [<xref rid="bib2" ref-type="bibr">2</xref>]. Coronary artery and peripheral vascular disease are the primary contributors to the global burden of CVD [<xref rid="bib3" ref-type="bibr">3</xref>]. Projections from the Global Burden of Disease (GBD) 2019 study estimated a 90&#160;% increase in cardiovascular prevalence, a 73.4&#160;% rise in crude mortality, and a 54.7&#160;% growth in crude disability-adjusted life years between 2025 and 2050, with cardiovascular deaths anticipated to climb from 20.5 million in 2025 to 35.6 million by 2050 [<xref rid="bib4" ref-type="bibr">4</xref>]. In Europe, CVD account for 39&#160;% of all deaths in men and 46&#160;% of all deaths in women [<xref rid="bib5" ref-type="bibr">5</xref>], whereas in the United States, coronary heart disease causes one in seven deaths [<xref rid="bib6" ref-type="bibr">6</xref>], with heart failure responsible for one in nine [<xref rid="bib6" ref-type="bibr">6</xref>]. Despite reductions in overall CVD mortality in South Korea, ischemic heart disease remains a growing concern [<xref rid="bib7" ref-type="bibr">7</xref>]. The primary driver of these diseases is arterial thrombosis resulting from atherosclerosis, often triggered by plaque rupture [<xref rid="bib8" ref-type="bibr">8</xref>]. While platelets are critical for maintaining hemostasis under normal conditions, they can become hyperactivated, leading to thrombotic complications [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. Such complications including ischemic stroke and myocardial infarction underscore the importance of targeting platelet activation and thrombus formation to prevent and manage CVD [<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib12" ref-type="bibr">12</xref>].</p><p id="p0015">In recent years, natural compounds have been recognized as safer alternatives to traditional synthetic drugs for managing inflammatory and cardiovascular diseases [<xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>]. Among these, ginseng, particularly <italic toggle="yes">Panax ginseng</italic>, has been particularly valued for its well-documented health benefits <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib47" ref-type="bibr">[19]</xref>, <xref rid="bib48" ref-type="bibr">[20]</xref>. Ginsenosides, the active saponins derived from ginseng, are known for their anti-inflammatory, antioxidant, and cardioprotective properties [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib19" ref-type="bibr">21</xref>]. Ginseng can improve endothelial function [<xref rid="bib20" ref-type="bibr">22</xref>], reduce oxidative stress [<xref rid="bib21" ref-type="bibr">23</xref>], and regulate lipid metabolism [<xref rid="bib22" ref-type="bibr">24</xref>], all of which are beneficial for heart health. On the other hand, the utility of current synthetic antiplatelet therapies, such as aspirin and P2Y12 inhibitors, although effective, is often limited by adverse effects such as gastrointestinal bleeding, platelet resistance, and increased bleeding risks, especially with long-term use [<xref rid="bib23" ref-type="bibr">25</xref>]. These adverse effects underscore the need for safer and more effective alternatives. Therefore, ginseng and its constituents, such as ginsenoside Rg5, may offer promise in terms of its ability to enhance cardioprotection while causing minimal adverse effects compared to its conventional synthetic counterpart treatments.</p><p id="p0020">Rg5 is a minor ginsenoside, resulting from the deglycosylation of Rb1 and dehydration at carbon position 20 of Rg3 [<xref rid="bib24" ref-type="bibr">26</xref>]. Unlike major ginsenosides, Rg5 exhibits enhanced pharmacological properties, including antitumor, anti-inflammatory, antidiabetic, neuroprotective, and cardioprotective activities [<xref rid="bib24" ref-type="bibr">26</xref>]. Rg5 enhances vascular health by promoting neovascularization and vasorelaxation through insulin-like growth factor-1 receptor (IGF-1R) activation, which triggers angiogenic signaling, thereby improving endothelial function under pathological conditions [<xref rid="bib25" ref-type="bibr">27</xref>]. Additionally, it protects cardiomyocytes from ischemic injury by modulating mitochondrial dynamics via hexokinase-II (HK-II) and dynamin-related protein 1 (Drp1), suppressing Drp1 activation and promoting HK-II binding through Akt activation [<xref rid="bib26" ref-type="bibr">28</xref>]. Rg5 has been reported to inhibit arachidonic acid-induced platelet aggregation, highlighting its potential as an antiplatelet agent [<xref rid="bib27" ref-type="bibr">29</xref>]. However, while previous studies have screened Rg5 for its antiplatelet activity, we provide the first mechanistic evidence of its specific antiplatelet effects (Graphical abstract). These findings support the hypothesis that Rg5 may offer a promising therapeutic option, providing enhanced cardioprotection while potentially reducing the adverse effects associated with conventional synthetic treatments.</p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><p id="p0025">A comprehensive description of the chemical reagents and experimental procedures, including the animal handling, preparation of human and rat platelets, assessment of <italic toggle="yes">in vitro</italic> parameters, and <italic toggle="yes">in vivo</italic> study protocols, is provided in the Supplementary Material.</p></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Rg5 exhibits potent antiplatelet activities without cytotoxicity</title><p id="p0030"><xref rid="fig1" ref-type="fig">Fig. 1</xref>A illustrates the molecular structure of ginsenoside Rg5. Light transmission aggregometry was performed by incubating hPRP with Rg5 at concentrations of 35, 50, 75, and 100&#160;&#956;M, in the presence of collagen (2.5&#160;&#956;g/mL) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B), thrombin (2.5 U/mL) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C), and U46619 (200&#160;nM) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>D). Rg5 significantly inhibited collagen-induced platelet aggregation at 35&#160;&#956;M and fully inhibited it at 100&#160;&#956;M. In contrast, Rg5 at 35&#160;&#956;M did not significantly affect thrombin (2.5 U/mL), and U46619 (200&#160;nM) induced platelet aggregation but significantly inhibited aggregation at concentrations between 50 and 100&#160;&#956;M. These results suggest that Rg5 strongly inhibits platelet aggregation through the collagen receptor (GPVI) pathway. The IC<sub>50</sub> of Rg5 was calculated to be 42.5&#160;&#956;M (<xref rid="fig1" ref-type="fig">Fig. 1</xref>E). This value indicates the potency of Rg5 in inhibiting platelet aggregation in our experimental setup. The cytotoxicity of Rg5 was evaluated using an LDH leakage assay (<xref rid="fig1" ref-type="fig">Fig. 1</xref>F). Our results demonstrated that Rg5 at 35&#8211;100&#160;&#956;M concentrations did not induce significant cytotoxicity in platelets, indicating its safety at these concentrations.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Rg5 inhibits platelet aggregation without exhibiting cytotoxicity</bold></p><p>(A) Molecular structure of ginsenoside Rg5. Light transmission aggregometry of human platelets pre-incubated with Rg5 (35&#8211;100&#160;&#956;M) and stimulated with collagen (2.5&#160;&#956;g/mL) (B), thrombin (2.5 U/mL) (C), or U46619 (200&#160;nM) (D). At 35&#160;&#956;M, Rg5 significantly inhibited collagen-induced platelet aggregation, whereas at 100&#160;&#956;M, complete inhibition was observed. Rg5 did not inhibit thrombin- and U46619-induced aggregation at 35&#160;&#956;M but showed dose-dependent inhibition from 50 to 100&#160;&#956;M, indicating its stronger activity on the GPVI receptor pathway. (E) The IC<sub>50</sub> value of Rg5 for collagen-induced platelet aggregation was calculated as 42.5&#160;&#956;M. (F) The lactate dehydrogenase (LDH) cytotoxicity assay confirmed no significant cytotoxic effects at 35&#8211;100&#160;&#956;M &#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 versus each agonist-stimulated human platelet. NS, not significant.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec3.2"><label>3.2</label><title>Rg5 inhibits collagen-induced platelet granular release and associated signaling pathways</title><p id="p0035">Rg5 (35&#8211;100&#160;&#956;M) strongly inhibits collagen-induced platelet granular release and related signaling pathways in human platelets (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). The results highlight the dose-dependent modulation of calcium mobilization, granular secretion, and the expression of associated proteins. A significant and dose-dependent reduction in intracellular calcium levels was observed (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A), indicating a direct impact on platelet activation signaling. Further, our results show that Rg5 significantly suppresses serotonin release with stronger inhibition at higher doses (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B). Similarly, ATP release was also dose-dependently inhibited by Rg5, with complete inhibition achieved at the highest concentration of 100&#160;&#956;M (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C). The release of &#945;-granules was assessed via CD62P expression and was found to be markedly reduced at 100&#160;&#956;M Rg5, showing its potent suppressive effect on platelet degranulation <xref rid="fig2" ref-type="fig">Fig. 2</xref>D.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Rg5 suppresses platelet granular secretion and intracellular signaling</bold></p><p>(A) Calcium mobilization was significantly inhibited in collagen-stimulated human platelets pre-incubated with Rg5 (35&#8211;100&#160;&#956;M). (B) Serotonin release was reduced significantly at all indicated Rg5 concentrations. (C) ATP release was dose-dependently inhibited, with complete inhibition observed at 100&#160;&#956;M Rg5. (D) The expression of CD62P, a marker of platelet degranulation, was significantly reduced at 100&#160;&#956;M Rg5. (E) Western blot analysis showed upregulation of p-InsP<sub>3</sub>R and downregulation of p-ERK and p-MARCKS compared to &#946;-actin, indicating Rg5 modulates key signaling pathways involved in platelet activation. &#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 versus the collagen-stimulated human platelets.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0040">The inositol-1,4,5-trisphosphate receptor type I (InsP<sub>3</sub>R) and extracellular signal-regulated kinase (ERK) regulate intracellular Ca<sup>2+</sup> concentration [<xref rid="bib28" ref-type="bibr">30</xref>]. Myristoylated alanine-rich C kinase substrate (MARCKS), binds to actin and is phosphorylated by phorbol 12-myristate 13-acetate (PMA), a PKC activator and plays a role in platelet exocytosis [<xref rid="bib29" ref-type="bibr">31</xref>]. Our Western blot results indicated the molecular changes induced by Rg5, including the upregulation of p-InsP<sub>3</sub>R and the downregulation of p-ERK and p-MARCKS, relative to &#946;-actin (<xref rid="fig2" ref-type="fig">Fig. 2</xref>E). These findings suggest that Rg5 strongly modulates critical signaling pathways involved in platelet activation.</p></sec><sec id="sec3.3"><label>3.3</label><title>Rg5 inhibits thromboxane A<sub>2</sub> (TXA<sub>2</sub>) production and downregulates TXA<sub>2</sub> signaling proteins</title><p id="p0045">Rg5 inhibits TXA<sub>2</sub> production and associated signaling pathways, emphasizing its role in suppressing platelet activation and aggregation [<xref rid="bib6" ref-type="bibr">6</xref>]. <xref rid="fig3" ref-type="fig">Fig. 3</xref>A demonstrates a significant and dose-dependent reduction in TXA<sub>2</sub> levels when platelets are treated with Rg5, indicating its inhibitory effect on this pro-aggregatory mediator. Additionally, <xref rid="fig3" ref-type="fig">Fig. 3</xref>B shows the downregulation of phosphorylated cytosolic phospholipase A<sub>2</sub> (p-cPLA<sub>2</sub>) and phosphorylated p38 MAPK (p-p38) compared to &#946;-actin, suggesting that Rg5 suppresses critical proteins in the TXA<sub>2</sub> signaling pathway.<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Rg5 inhibits TXA<sub>2</sub> production and key signaling pathways</bold></p><p>(A) The levels of TXB<sub>2</sub>, a stable metabolite of TXA<sub>2</sub>, were significantly reduced at all tested concentrations of Rg5 (35&#8211;100&#160;&#956;M) in collagen-stimulated platelets. (B) Western blot analysis revealed dose-dependent downregulation of p-cPLA<sub>2</sub> and p-p38 compared to &#946;-actin, indicating Rg5 suppresses TXA<sub>2</sub> synthesis and MAPK signaling in platelets. &#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, versus the collagen-stimulated human platelets.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.4"><label>3.4</label><title>Rg5 inhibits fibrinogen binding, fibronectin adhesion, and thrombin-induced clot retraction</title><p id="p0050">FACS analysis demonstrated that Rg5 at 100&#160;&#956;M significantly reduced collagen-induced fibrinogen binding in platelets, showing similar levels to intact (unstimulated) platelets (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A). Rg5 at 100&#160;&#956;M significantly inhibited fibrinogen binding, aligning closely with control levels (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B). Our results further reveal that Rg5 inhibits platelet adhesion to fibronectin significantly with 35&#8211;100&#160;&#956;M concentrations, further highlighting its inhibitory effect on platelet adhesion (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C). Rg5 also inhibited thrombin-induced clot retraction at concentrations of 35&#8211;100&#160;&#956;M. For comparison, the Rho kinase inhibitor Y27632 demonstrated a similar potency to Rg5. <xref rid="fig4" ref-type="fig">Fig. 4</xref>E shows the clot area, showing that Rg5 significantly increases the clot area and effectively prevents clot retraction.<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>Rg5 suppresses fibrinogen binding, fibronectin adhesion, and clot retraction</bold></p><p>(A) FACS analysis of fibrinogen binding shows that Rg5 at 100&#160;&#956;M significantly inhibited collagen-induced platelet fibrinogen activation, comparable to intact platelets used as a control. (B) Quantification of fibrinogen binding demonstrates a significant reduction at 100&#160;&#956;M Rg5, aligning with the levels observed in intact platelets. (C) Fibronectin adhesion was significantly and dose-dependently inhibited by Rg5 at concentrations ranging from 35 to 100&#160;&#956;M. (D) Thrombin-induced clot retraction was markedly inhibited by Rg5 (35&#8211;100&#160;&#956;M), with effects comparable to Y27632. (E) Quantitative analysis of clot area (mm<sup>2</sup>) indicates that Rg5 significantly increased clot area, effectively preventing clot retraction. &#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 versus the collagen and thrombin stimulated human platelets.</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.5"><label>3.5</label><title>Rg5 modulates intracellular signaling pathways and platelet adhesion markers</title><p id="p0055">Rg5 downregulates the phosphorylation of PI<sub>3</sub>K (p-PI<sub>3</sub>K), AKT (p-AKT), GSK-3&#945;/&#946; (p-GSK-3&#945;/&#946;), and Syk (p-Syk), alongside the upregulation of phosphorylated VASP at serine 157 (p-VASP(S157)) and serine 239 (p-VASP(S239)) in a dose-dependent manner (35&#8211;100&#160;&#956;M). Our results demonstrated that Rg5 inhibits pro-aggregatory signaling pathways while promoting inhibitory signaling cascades in platelets (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A). Further, Rg5 significantly and dose-dependently increased intracellular cAMP and cGMP levels at 35&#8211;100&#160;&#956;M. This indicates an enhancement of cyclic nucleotide-mediated platelet inhibition. CD162 is expressed on neutrophils [<xref rid="bib30" ref-type="bibr">32</xref>]. We further analyzed the suppressive effects of Rg5 on platelet-leukocyte aggregates. Our results indicated that Collagen&#160;+&#160;oxLDL-induced CD162 expression was significantly reduced by Rg5 at 100&#160;&#956;M (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C). This reduction highlights the ability of Rg5 to attenuate platelet adhesion and interaction with leukocytes under atherogenic conditions.<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>Rg5 modulates platelet signaling pathways and inhibits ox-LDL-induced CD162 expression</bold></p><p>(A) Western blot analysis shows that Rg5 (35&#8211;100&#160;&#956;M) downregulates the phosphorylation of p-PI<sub>3</sub>K, p-AKT, p-GSK-3&#945;/&#946;, and p-Syk while upregulating the phosphorylation of p-VASP(S157) and p-VASP(S239). (B) ELISA data reveal that Rg5 dose-dependently and significantly increases the levels of cAMP and cGMP in platelets at 35&#8211;100&#160;&#956;M. (C) Flow cytometry analysis demonstrates that 100&#160;&#956;M Rg5 significantly inhibits collagen (2.5&#160;&#956;g/mL)&#160;+&#160;oxLDL-induced CD162 expression, highlighting its protective role against oxLDL-mediated platelet activation. &#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 versus the collagen and collagen&#160;+&#160;oxLDL-stimulated human platelets.</p></caption><alt-text id="alttext0040">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec3.6"><label>3.6</label><title>Effect of Rg5 on FeCl<sub>3</sub>-induced thrombosis and left carotid artery occlusion time</title><p id="p0060">The antithrombotic effects of Rg5 were evaluated using the FeCl<sub>3</sub>-induced thrombosis model in mice. Treatment with Rg5 was compared with aspirin and vehicle (FeCl<sub>3</sub>) groups. FeCl<sub>3</sub>-induced thrombus formation was significantly reduced in the 20&#160;mg/kg Rg5 group, with Rg5 proving to be more effective than aspirin in preventing thrombus formation (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). The occlusion time (time taken for blood flow to stop in the left carotid artery) was prolonged by Rg5 treatment than in the vehicle group, suggesting that Rg5 helps maintain blood flow by inhibiting thrombus formation.<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><bold>Rg5 prevents FeCl<sub>3</sub>-induced thrombosis and prolongs carotid artery occlusion time</bold></p><p>(A) FeCl<sub>3</sub>-induced thrombus was significantly prevented after treatment with Rg5 at 20&#160;mg/kg, with efficacy better than that of aspirin (100&#160;mg/kg). (B) Carotid artery occlusion time was significantly prolonged in Rg5-treated groups (10 and 20&#160;mg/kg) compared to the vehicle, demonstrating potent antithrombotic effects. (C) H&amp;E staining of the FeCl<sub>3</sub>-induced thrombus revealed substantial prevention of thrombus formation in Rg5-treated groups compared to the vehicle control group, further supporting the antithrombotic activity of Rg5. &#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, &#8727;&#8727;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01 versus the Vehicle (FeCl<sub>3</sub> only).</p></caption><alt-text id="alttext0045">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0065">Rg5 inhibited collagen, thrombin, and U46619-induced platelet aggregation, with the strongest effect on collagen-induced aggregation via the GPVI receptor (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). These results suggest that Rg5 preferentially targets GPVI-mediated signaling pathways, which are critical for platelet activation and thrombus formation [<xref rid="bib31" ref-type="bibr">33</xref>,<xref rid="bib32" ref-type="bibr">34</xref>]. Further, our data reveal that Rg5 significantly inhibits intracellular calcium mobilization ([Ca<sup>2+</sup>]i), a key secondary messenger in platelet activation [<xref rid="bib33" ref-type="bibr">35</xref>,<xref rid="bib34" ref-type="bibr">36</xref>]. The observed reduction in calcium signaling by Rg5 affects InsP3R function and suppresses upstream signaling proteins, such as p-cPLA<sub>2</sub> and p-p38 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A and E). These molecules are critical regulators of calcium release from intracellular stores, and their inhibition by Rg5 suggests a direct interference with pathways essential for platelet activation as reported previously and recently [<xref rid="bib35" ref-type="bibr">[37]</xref>, <xref rid="bib36" ref-type="bibr">[38]</xref>, <xref rid="bib37" ref-type="bibr">[39]</xref>]. Furthermore, Rg5 reduced ATP and serotonin release, key markers of dense granule secretion, in a dose-dependent manner (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B and C). This indicates suppression of platelet degranulation, an essential step for sustained platelet activation and recruitment. The reduction in CD62P (P-selectin) expression further confirms the inhibition of &#945;-granule release (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D). This plays a significant role in platelet-platelet and platelet-endothelium interactions during thrombus formation [<xref rid="bib38" ref-type="bibr">40</xref>].</p><p id="p0070">Rg5 significantly inhibited TXB<sub>2</sub> production, a stable metabolite of TXA<sub>2</sub>, an inducer of platelet aggregation and vasoconstriction [<xref rid="bib39" ref-type="bibr">41</xref>](<xref rid="fig3" ref-type="fig">Fig. 3</xref>). The downregulation of p-cPLA<sub>2</sub>, a key enzyme in TXA<sub>2</sub> synthesis, further supports the ability of Rg5 to inhibit TXA<sub>2</sub> signaling [<xref rid="bib40" ref-type="bibr">42</xref>]. Rg5 also inhibited thrombin-induced clot retraction, an integrin &#945;IIb&#946;3-mediated process that contributes to thrombus stabilization [<xref rid="bib41" ref-type="bibr">43</xref>](<xref rid="fig4" ref-type="fig">Fig. 4</xref>). This effect was accompanied by an increase in clot area, indicating that it disrupts the final common pathway of platelet aggregation, which involves these molecules bridging activated platelets [<xref rid="bib42" ref-type="bibr">44</xref>].</p><p id="p0075">Western blot analysis revealed that Rg5 downregulated key signaling proteins involved in platelet activation, including p-ERK, p-p38, p-Syk, and p-GSK-3&#945;/&#946; (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A). These kinases are critical mediators of GPVI, thrombin, and TX receptor signaling [<xref rid="bib43" ref-type="bibr">45</xref>]. Notably, the inhibition of p-Syk and p-ERK highlights the ability of Rg5 to interfere with the early stages of GPVI-mediated signaling cascades. Interestingly, Rg5 upregulated the phosphorylation of VASP at Ser157 and Ser239, which are associated with increased cAMP and cGMP signaling, respectively. One possible explanation is that Rg5 may modulate VASP phosphorylation through alternative pathways, such as inhibition of phosphodiesterase enzymes or direct effects on PKA and (PKG (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B). Rg5 inhibited collagen&#160;+&#160;oxLDL-induced CD162 (PSGL-1) expression (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C). This is a critical finding because CD162 is involved in platelet-leukocyte interactions, playing an important role in inflammation and atherothrombosis [<xref rid="bib44" ref-type="bibr">46</xref>]. OxLDL is known to enhance platelet activation through pathways involving CD162 and other adhesion molecules [<xref rid="bib44" ref-type="bibr">46</xref>,<xref rid="bib45" ref-type="bibr">47</xref>]. By inhibiting platelet-leukocyte aggregation, Rg5 not only attenuates platelet aggregation but also reduces the inflammatory component of thrombus formation.</p><p id="p0080">I<italic toggle="yes">n vivo,</italic> FeCl<sub>3</sub>-induced thrombosis model in mice provided further evidence of its antithrombotic potential, with 20&#160;mg/kg Rg5 significantly prolonging occlusion time and reducing thrombus formation more effectively than aspirin (<xref rid="fig6" ref-type="fig">Fig. 6</xref>) [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib46" ref-type="bibr">48</xref>].</p><p id="p0085">Rg5 inhibits platelet activation and thrombus formation while demonstrating no cytotoxicity, highlighting its potential as a therapeutic agent for thrombotic cardiovascular diseases. Compared to conventional antiplatelet drugs such as aspirin, Rg5 offers a broader spectrum of activity with potentially fewer adverse effects. However, further studies are needed to explore its pharmacokinetics, bioavailability, and long-term safety profile. Furthermore, it is crucial to identify the specific molecular targets of Rg5 and its interactions with other signaling pathways for advancing the clinical development of this compound. In conclusion, this study provides novel mechanistic insights into the antiplatelet activity of Rg5, demonstrating its potential as a safer and more effective therapeutic agent to prevent thrombotic disorders.</p></sec><sec id="sec5"><title>Author's contribution</title><p id="p0090">Abdul Wahab Akram and Jung-Hae Shin: Experimental data procurement, Analysis, writing original draft; review and editing the manuscript. Uyanga Batmunkh, Evelyn Saba, Yong-Myung Kang, Sunjun Jung, Jee Eun Han, Sung Dae Kim, and Dongmi Kwak: Technical help, Final review, and editing. Hyuk-woo Kwon and Man Hee Rhee: Conceptualization, Supervision, Funding acquisition, Investigation, Project administration, Resources, and support.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0095">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Gaidai</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Loginov</surname><given-names>S.</given-names></name></person-group><article-title>Global cardiovascular diseases death rate prediction</article-title><source>Curr Probl Cardiol</source><volume>48</volume><year>2023</year><object-id pub-id-type="publisher-id">101622</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpcardiol.2023.101622</pub-id><pub-id pub-id-type="pmid">36724816</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Almetairi</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Alasmari</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Makkawi</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>A.A.</given-names></name></person-group><article-title>Prevalence, hematological parameters, and coagulation profiles: cardiovascular diseases statistics in the Asir region, Saudi Arabia</article-title><source>Saudi Med J</source><volume>44</volume><year>2023</year><fpage>385</fpage><pub-id pub-id-type="pmid">37062554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15537/smj.2023.44.4.20220746</pub-id><pub-id pub-id-type="pmcid">PMC10153605</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>U.</given-names></name><name name-style="western"><surname>Babcock</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akbarnejad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wirtz</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Laliberte</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Real-world incidence of adverse clinical outcomes among people with coronary artery disease and/or peripheral artery disease in relation to vascular risk in the United States</article-title><source>Am J Cardiol</source><volume>208</volume><year>2023</year><fpage>44</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">37812866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2023.08.110</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jayabaskaran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jauhari</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kueh</surname><given-names>M.T.W.</given-names></name><etal/></person-group><article-title>Global burden of cardiovascular diseases: projections from 2025 to 2050</article-title><source>Eur J Prev Cardiol</source><year>2024</year><object-id pub-id-type="publisher-id">zwae281</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurjpc/zwae281</pub-id><pub-id pub-id-type="pmid">39270739</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kazakiewicz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lucy Wright</surname><given-names>F.</given-names></name><name name-style="western"><surname>Timmis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huculeci</surname><given-names>R.</given-names></name><name name-style="western"><surname>Torbica</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Epidemiology of cardiovascular disease in Europe</article-title><source>Nat Rev Cardiol</source><volume>19</volume><year>2022</year><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">34497402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-021-00607-3</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Irfan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>M.H.</given-names></name></person-group><article-title>Pharmacological actions of dieckol on modulation of platelet functions and thrombus formation via integrin &#945;IIb&#946;3 and cAMP signaling</article-title><source>Pharmacol Res</source><volume>177</volume><year>2022</year><object-id pub-id-type="publisher-id">106088</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2022.106088</pub-id><pub-id pub-id-type="pmid">35038555</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>H.-E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.-J.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-S.</given-names></name></person-group><article-title>Participation and prognostic impact of cardiac rehabilitation after acute coronary syndrome: big-data study of the Korean National Health Insurance Service</article-title><source>J Kor Med Sci</source><volume>38</volume><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.2023.38.e119</pub-id><pub-id pub-id-type="pmcid">PMC10111042</pub-id><pub-id pub-id-type="pmid">37069813</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Grover</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Mackman</surname><given-names>N.</given-names></name></person-group><article-title>Tissue factor in atherosclerosis and atherothrombosis</article-title><source>Atherosclerosis</source><volume>307</volume><year>2020</year><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">32674807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2020.06.003</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Vulliamy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>P.C.</given-names></name></person-group><article-title>Platelets in hemostasis, thrombosis, and inflammation after major trauma</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>44</volume><year>2024</year><fpage>545</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">38235557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.123.318801</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Saba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>M.H.</given-names></name></person-group><article-title>Antiplatelet and antithrombotic activities of Lespedeza cuneata via pharmacological inhibition of integrin &#945;IIb&#946;3, MAPK, and PI3K/AKT pathways and FeCl3&#8208;induced murine thrombosis</article-title><source>Evid base Compl Alternative Med</source><volume>2024</volume><year>2024</year><object-id pub-id-type="publisher-id">9927160</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2024/9927160</pub-id><pub-id pub-id-type="pmcid">PMC10872769</pub-id><pub-id pub-id-type="pmid">38370873</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Giurranna</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nencini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bettiol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Argento</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Emmi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Dietary antioxidants and natural compounds in preventing thrombosis and cardiovascular disease</article-title><source>Int J Mol Sci</source><volume>25</volume><year>2024</year><object-id pub-id-type="publisher-id">11457</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms252111457</pub-id><pub-id pub-id-type="pmcid">PMC11546393</pub-id><pub-id pub-id-type="pmid">39519009</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Mohd Nor</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Othman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mohd</surname><given-names>Tohit ER.</given-names></name><name name-style="western"><surname>Md Noor</surname><given-names>S.</given-names></name></person-group><article-title>Medicinal herbals with antiplatelet properties benefit in coronary atherothrombotic diseases</article-title><source>Thrombosis</source><volume>2016</volume><year>2016</year><object-id pub-id-type="publisher-id">5952910</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/5952910</pub-id><pub-id pub-id-type="pmcid">PMC4808659</pub-id><pub-id pub-id-type="pmid">27051529</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Shaito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thuan</surname><given-names>D.T.B.</given-names></name><name name-style="western"><surname>Phu</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.H.D.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Halabi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety</article-title><source>Front Pharmacol</source><volume>11</volume><year>2020</year><fpage>422</fpage><pub-id pub-id-type="pmid">32317975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.00422</pub-id><pub-id pub-id-type="pmcid">PMC7155419</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Wahab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Antioxidant and anti-inflammatory activities of Lespedeza cuneata in Coal fly ash-induced murine alveolar macrophage cells</article-title><source>Kor J Vet Res</source><volume>63</volume><year>2023</year><comment>27-21</comment></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Batmunkh</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>M.H.</given-names></name></person-group><article-title>In-vitro evaluation of free radical scavenging activities and inflammatory markers from LPS-induced MH-S cells by Xanthium strumarium L</article-title><source>Microbiology and Biotechnology Letters</source><volume>52</volume><issue>4</issue><year>2024</year><fpage>462</fpage><lpage>469</lpage></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Saba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Innovative use of a commercial product (Biomagic) for odor reduction, harmful bacteria inhibition, and immune enhancement in pig farm</article-title><source>Korean J Vet Res</source><volume>64</volume><year>2024</year><fpage>e32</fpage></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Uyanga</surname><given-names>Batmunkh AWA.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>Dae K.</given-names></name><name name-style="western"><surname>Tae-Wan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Man Hee</surname><given-names>R.</given-names></name></person-group><article-title>Anti-inflammatory properties of Eupatorium japonicum in LPS-induced RAW 264.7 cells</article-title><source>J Prev Vet Med</source><volume>48</volume><year>2024</year><fpage>241</fpage><lpage>251</lpage></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Overview of Panax ginseng and its active ingredients protective mechanism on cardiovascular diseases</article-title><source>J Ethnopharmacol</source><year>2024</year><object-id pub-id-type="publisher-id">118506</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2024.118506</pub-id><pub-id pub-id-type="pmid">38964625</pub-id></element-citation></ref><ref id="bib47"><label>19</label><element-citation publication-type="journal" id="opt4wz5qZjGot"><person-group person-group-type="author"><name name-style="western"><surname>KWON</surname><given-names>Hyuk-Woo</given-names></name><etal/></person-group><article-title>Anti-thrombotic effects of ginsenoside Rk3 by regulating cAMP and PI3K/MAPK pathway on human platelets</article-title><source>J. Ginseng Res.</source><volume>47</volume><issue>6</issue><year>2023</year><fpage>706</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">38107398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgr.2023.04.006</pub-id><pub-id pub-id-type="pmcid">PMC10721468</pub-id></element-citation></ref><ref id="bib48"><label>20</label><element-citation publication-type="journal" id="optpcg8PVWPC6"><person-group person-group-type="author"><name name-style="western"><surname>Yuan Yee</surname></name><etal/></person-group><article-title>The anti-platelet activity of panaxadiol fraction and panaxatriol fraction of Korean Red Ginseng in vitro and ex vivo</article-title><source>J. Ginseng Res.</source><volume>47</volume><issue>5</issue><year>2023</year><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">37720569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgr.2023.03.003</pub-id><pub-id pub-id-type="pmcid">PMC10499584</pub-id></element-citation></ref><ref id="bib19"><label>21</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Hyun</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bhilare</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>G Park</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-H.</given-names></name></person-group><article-title>Effects of Panax ginseng and ginsenosides on oxidative stress and cardiovascular diseases: pharmacological and therapeutic roles</article-title><source>J Ginseng Res</source><volume>46</volume><year>2022</year><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">35058725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgr.2021.07.007</pub-id><pub-id pub-id-type="pmcid">PMC8753520</pub-id></element-citation></ref><ref id="bib20"><label>22</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Won</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>K.-S.</given-names></name><etal/></person-group><article-title>Korean Red ginseng prevents endothelial senescence by downregulating the HO-1/NF-&#954;B/miRNA-155-5p/eNOS pathway</article-title><source>J Ginseng Res</source><volume>45</volume><year>2021</year><fpage>344</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">33841015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgr.2020.08.002</pub-id><pub-id pub-id-type="pmcid">PMC8020293</pub-id></element-citation></ref><ref id="bib21"><label>23</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Effects of ginseng consumption on the biomarkers of oxidative stress: a systematic review and meta&#8208;analysis</article-title><source>Phytother Res</source><volume>37</volume><year>2023</year><fpage>3262</fpage><lpage>3274</lpage><pub-id pub-id-type="pmid">37216939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ptr.7893</pub-id></element-citation></ref><ref id="bib22"><label>24</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.-S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.-R.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>F.-J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Ameliorative effects of malonyl ginsenoside from Panax ginseng on glucose-lipid metabolism and insulin resistance via IRS1/PI3K/Akt and AMPK signaling pathways in type 2 diabetic mice</article-title><source>Am J Chin Med</source><volume>50</volume><year>2022</year><fpage>863</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">35282802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S0192415X22500367</pub-id></element-citation></ref><ref id="bib23"><label>25</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Chandiramani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>M.S.</given-names></name></person-group><article-title>Should we use aspirin or P2Y12 inhibitor monotherapy in stable ischemic heart disease?</article-title><source>Curr Atheroscler Rep</source><year>2024</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11883-024-01234-2</pub-id><pub-id pub-id-type="pmid">39243345</pub-id></element-citation></ref><ref id="bib24"><label>26</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.-Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J.-N.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.-Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.-G.</given-names></name><etal/></person-group><article-title>Pharmacological activities of ginsenoside Rg5</article-title><source>Exp Ther Med</source><volume>22</volume><year>2021</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2021.10272</pub-id><pub-id pub-id-type="pmcid">PMC8210315</pub-id><pub-id pub-id-type="pmid">34149886</pub-id></element-citation></ref><ref id="bib25"><label>27</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Hur</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.-K.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Specific activation of insulin-like growth factor-1 receptor by ginsenoside Rg5 promotes angiogenesis and vasorelaxation</article-title><source>J Biol Chem</source><volume>290</volume><year>2015</year><fpage>467</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">25391655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M114.603142</pub-id><pub-id pub-id-type="pmcid">PMC4281749</pub-id></element-citation></ref><ref id="bib26"><label>28</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Ginsenoside Rg5 increases cardiomyocyte resistance to ischemic injury through regulation of mitochondrial hexokinase-II and dynamin-related protein 1</article-title><source>Cell Death Dis</source><volume>8</volume><year>2017</year><comment>e2625-e2625</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2017.43</pub-id><pub-id pub-id-type="pmcid">PMC5386487</pub-id><pub-id pub-id-type="pmid">28230856</pub-id></element-citation></ref><ref id="bib27"><label>29</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Pyo</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Yun-Choi</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name></person-group><article-title>Platelet antiaggregating activity of ginsenosides isolated from processed ginseng</article-title><source>Pharmazie-Int Res J Pharmaceut Sci</source><volume>64</volume><year>2009</year><fpage>602</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">19827304</pub-id></element-citation></ref><ref id="bib28"><label>30</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>H.Y.F.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tantiwong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahrends</surname><given-names>R.</given-names></name><etal/></person-group><article-title>High-throughput assessment identifying major platelet Ca2+ entry pathways via tyrosine kinase-linked and G protein-coupled receptors</article-title><source>Cell Calcium</source><volume>112</volume><year>2023</year><object-id pub-id-type="publisher-id">102738</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ceca.2023.102738</pub-id><pub-id pub-id-type="pmid">37060673</pub-id></element-citation></ref><ref id="bib29"><label>31</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diekmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoffmeister</surname><given-names>L.</given-names></name><name name-style="western"><surname>K&#252;hl</surname><given-names>F.</given-names></name><name name-style="western"><surname>Welz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brand</surname><given-names>K.</given-names></name></person-group><article-title>MARCKS is an essential regulator of reactive oxygen species production in the monocytic cell type</article-title><source>Antioxidants</source><volume>11</volume><year>2022</year><fpage>1600</fpage><pub-id pub-id-type="pmid">36009319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11081600</pub-id><pub-id pub-id-type="pmcid">PMC9404745</pub-id></element-citation></ref><ref id="bib30"><label>32</label><element-citation publication-type="book" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Granai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Warm</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vogelsberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Milla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Greif</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>U.</given-names></name><etal/></person-group><series>Impact of P-selectin&#8211;PSGL-1 Axis on platelet-endothelium-leukocyte interactions in fatal COVID-19</series><volume>vol. 103</volume><year>2023</year><publisher-name>Laboratory Investigation</publisher-name><object-id pub-id-type="publisher-id">100179</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.labinv.2023.100179</pub-id><pub-id pub-id-type="pmcid">PMC10202465</pub-id><pub-id pub-id-type="pmid">37224922</pub-id></element-citation></ref><ref id="bib31"><label>33</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Glaucocalyxin A inhibits platelet activation and thrombus formation preferentially via GPVI signaling pathway</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e85120</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0085120</pub-id><pub-id pub-id-type="pmcid">PMC3875551</pub-id><pub-id pub-id-type="pmid">24386454</pub-id></element-citation></ref><ref id="bib32"><label>34</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes</surname><given-names>E.</given-names></name></person-group><article-title>Modulation of glycoprotein VI and its downstream signaling pathways as an antiplatelet target</article-title><source>Int J Mol Sci</source><volume>23</volume><year>2022</year><fpage>9882</fpage><pub-id pub-id-type="pmid">36077280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23179882</pub-id><pub-id pub-id-type="pmcid">PMC9456422</pub-id></element-citation></ref><ref id="bib33"><label>35</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Rink</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Sage</surname><given-names>S.O.</given-names></name></person-group><article-title>Calcium signaling in human platelets</article-title><source>Annu Rev Physiol</source><volume>52</volume><year>1990</year><fpage>431</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">2158766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.ph.52.030190.002243</pub-id></element-citation></ref><ref id="bib34"><label>36</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Irfan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling</article-title><source>Vasc Pharmacol</source><volume>109</volume><year>2018</year><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vph.2018.06.002</pub-id><pub-id pub-id-type="pmid">29890296</pub-id></element-citation></ref><ref id="bib35"><label>37</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Berridge</surname><given-names>M.J.</given-names></name></person-group><article-title>The inositol trisphosphate/calcium signaling pathway in health and disease</article-title><source>Physiol Rev</source><volume>96</volume><year>2016</year><fpage>1261</fpage><lpage>1296</lpage><pub-id pub-id-type="pmid">27512009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00006.2016</pub-id></element-citation></ref><ref id="bib36"><label>38</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Tryptanthrin impairs platelet function and thrombus formation by reducing Gp1b&#945; expression</article-title><source>Eur J Pharmacol</source><year>2025</year><object-id pub-id-type="publisher-id">177332</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2025.177332</pub-id><pub-id pub-id-type="pmid">39900328</pub-id></element-citation></ref><ref id="bib37"><label>39</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>P2Y12 receptor-independent antiplatelet mechanism of cryptotanshinone: network pharmacology and experimental validation of multi-target signaling pathways</article-title><source>J Ethnopharmacol</source><volume>341</volume><year>2025</year><object-id pub-id-type="publisher-id">119321</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2025.119321</pub-id><pub-id pub-id-type="pmid">39755188</pub-id></element-citation></ref><ref id="bib38"><label>40</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Heemskerk</surname><given-names>J.W.M.</given-names></name><name name-style="western"><surname>Bevers</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lindhout</surname><given-names>T.</given-names></name></person-group><article-title>Platelet activation and blood coagulation</article-title><source>Thromb Haemost</source><volume>88</volume><year>2002</year><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">12195687</pub-id></element-citation></ref><ref id="bib39"><label>41</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Braune</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#252;pper</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>F.</given-names></name></person-group><article-title>Effect of prostanoids on human platelet function: an overview</article-title><source>Int J Mol Sci</source><volume>21</volume><year>2020</year><fpage>9020</fpage><pub-id pub-id-type="pmid">33260972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21239020</pub-id><pub-id pub-id-type="pmcid">PMC7730041</pub-id></element-citation></ref><ref id="bib40"><label>42</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Eckenstaler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ripperger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hauke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hemkemeyer</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Schwedhelm</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A thromboxane A2 receptor-driven COX-2&#8211;dependent feedback loop that affects endothelial homeostasis and angiogenesis</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>42</volume><year>2022</year><fpage>444</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">35236104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.121.317380</pub-id><pub-id pub-id-type="pmcid">PMC8939709</pub-id></element-citation></ref><ref id="bib41"><label>43</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Qihuang Zhuyu formula alleviates coronary microthrombosis by inhibiting PI3K/Akt/&#945;IIb&#946;3-mediated platelet activation</article-title><source>Phytomedicine</source><volume>125</volume><year>2024</year><object-id pub-id-type="publisher-id">155276</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2023.155276</pub-id><pub-id pub-id-type="pmid">38295661</pub-id></element-citation></ref><ref id="bib42"><label>44</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Hsia</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Hsia</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Jayakumar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Velusamy</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Modulation of human platelet activation and in vivo vascular thrombosis by columbianadin: regulation by integrin &#945; IIb &#946; 3 inside-out but not outside-in signals</article-title><source>J Biomed Sci</source><volume>27</volume><year>2020</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">32375785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-020-0619-5</pub-id><pub-id pub-id-type="pmcid">PMC7201758</pub-id></element-citation></ref><ref id="bib43"><label>45</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Hsia</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>O.T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>T.L.</given-names></name><etal/></person-group><article-title>Ginkgetin effectively mitigates collagen and AA&#8208;induced platelet activation via PLC&#947;2 but not cyclic nucleotide&#8208;dependent pathway in human</article-title><source>J Cell Mol Med</source><volume>28</volume><year>2024</year><object-id pub-id-type="publisher-id">e18139</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.18139</pub-id><pub-id pub-id-type="pmcid">PMC10853947</pub-id><pub-id pub-id-type="pmid">38334198</pub-id></element-citation></ref><ref id="bib44"><label>46</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>M.H.</given-names></name></person-group><article-title>Panax ginseng: inflammation, platelet aggregation, thrombus formation, and atherosclerosis crosstalk</article-title><source>J Ginseng Res</source><volume>46</volume><year>2022</year><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">35058727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgr.2021.09.003</pub-id><pub-id pub-id-type="pmcid">PMC8753522</pub-id></element-citation></ref><ref id="bib45"><label>47</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Lugo-Gavidia</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>V.B.</given-names></name><name name-style="western"><surname>Nolde</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Galindo Kiuchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carnagarin</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Role of microparticles in cardiovascular disease: implications for endothelial dysfunction, thrombosis, and inflammation</article-title><source>Hypertension</source><volume>77</volume><year>2021</year><fpage>1825</fpage><lpage>1844</lpage><pub-id pub-id-type="pmid">33979187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.121.16975</pub-id></element-citation></ref><ref id="bib46"><label>48</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.D.</given-names></name><etal/></person-group><article-title>Characterization of ferric chloride-induced arterial thrombosis model of mice and the role of red blood cells in thrombosis acceleration</article-title><source>Yonsei Med J</source><volume>62</volume><year>2021</year><fpage>1032</fpage><pub-id pub-id-type="pmid">34672137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3349/ymj.2021.62.11.1032</pub-id><pub-id pub-id-type="pmcid">PMC8542466</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0105">The following is the supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgment</title><p id="p0100">This study received support from the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100015826</institution-id><institution>Korean Society of Ginseng</institution></institution-wrap></funding-source> (2023, H.W.K.), and the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source> (<funding-source id="gs3">NRF</funding-source>), which is funded by the government of South Korea (<funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100014188</institution-id><institution>MSIT</institution></institution-wrap></funding-source>) under grant No. <award-id award-type="grant" rid="gs4">2022R1A2C1012963</award-id>.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0110">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jgr.2025.04.002" id="intref0010">https://doi.org/10.1016/j.jgr.2025.04.002</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>